Tag debug info: client: {"assets":{},"datasets":{},"live":{},"projects":{},"users":{},"observable":{"assets":{},"datasets":{},"live":{},"projects":{},"users":{}}} Now: 1770475469593 Cache Key: cqdTagPageBySlug:gene-editing fetchCache[cqdTagPageBySlug:gene-editing].expirationTime: falsey fetchCache[cqdTagPageBySlug:gene-editing]. seconds remaining: falsey All fetchCache expiration times: -- Key: cqdNotFoundPage, seconds remaining: 127 -- Key: cqdTagPageBySlug:suneel-apte, seconds remaining: 127 -- Key: cqdPostsByTag:cqd-migrated-tag-16400,1,10, seconds remaining: 177 -- Key: cqdTagPageBySlug:wayne-tsuang, seconds remaining: 430 -- Key: cqdPostsByTag:cqd-migrated-tag-3577,1,10, seconds remaining: 493 -- Key: cqdTagPageBySlug:cerebral-microbleed, seconds remaining: 739 -- Key: cqdPostsByTag:cqd-migrated-tag-24480,1,10, seconds remaining: 797 -- Key: cqdTagPageBySlug:flexible-scheduling, seconds remaining: 1068 -- Key: cqdPostsByTag:cqd-migrated-tag-25407,1,10, seconds remaining: 1142 -- Key: cqdTagPageBySlug:antisense-oligonucleotide, seconds remaining: 1344 -- Key: cqdPostsByTag:cqd-migrated-tag-21669,1,10, seconds remaining: 1406 -- Key: cqdTagPageBySlug:isoform-2, seconds remaining: 1660 -- Key: cqdPostsByTag:cqd-migrated-tag-18236,1,10, seconds remaining: 1711 -- Key: cqdTagPageBySlug:patient-callbacks, seconds remaining: 3450 -- Key: cqdPostsByTag:cqd-migrated-tag-17648,1,10, seconds remaining: 3499 -- Key: cqdTagPageBySlug:john-mosher, seconds remaining: 6455 -- Key: cqdPostsByTag:cqd-migrated-tag-514,1,10, seconds remaining: 6512 -- Key: cqdTagPageBySlug:benjamin-walter, seconds remaining: 7686 -- Key: cqdPostsByTag:cqd-migrated-tag-19757,1,10, seconds remaining: 7734 -- Key: cqdTagPageBySlug:hearing-loss-screening, seconds remaining: 9118 -- Key: cqdPostsByTag:cqd-migrated-tag-23112,1,10, seconds remaining: 9169 conditions: -- false, -- NA, -- NA, -- NA -- false Cache miss for key cqdTagPageBySlug:gene-editing - retrieving from Sanity CCCache.dataFetchCount: 7346 Cache cleanup seconds remaining: 29118
Advertisement
Advertisement
First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival
Ethical considerations must include the impact on those who would carry children with modified genomes
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Rendered: Sat Feb 07 2026 14:44:29 GMT+0000 (Coordinated Universal Time)
9500 Euclid Avenue, Cleveland, Ohio 44195 |
800.223.2273 | ©
2026 Cleveland Clinic. All Rights Reserved.